NCT07919678ClinicalTrials.gov
A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)
En resumen
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of…
Fase 3656 participantes buscados40 centros2 países
Categorías
Registrado en 1 registro
- ClinicalTrials.govNCT07919678Abrir este registro en ClinicalTrials.govSincronizado hace 2 semanas
Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.
La información del ensayo se muestra tal como la publicó el registro, en su idioma original.
¿Le interesa este estudio?
Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 10 days after the recorded start)First posted 2026-11-05; recorded start 2026-10-26
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 635 other studies in this databaseCounted from the lead sponsor named in the record (Pfizer)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 3 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 40 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 656 participants (target), run at 40 sites, across 2 countries.
How this score is built
- Enrolment28/40
656 participants (target)
- Site count19/25
40 sites
- Country count7/15
2 countries
- Planned duration7/10
Planned over about 24 months
- Sponsor scale10/10
Pfizer has led 630 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Resumen
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.
Afecciones
- Obesity
- Overweight
- Osteoarthritis of the Knee
Elegibilidad
| Sexo | Todos |
|---|---|
| Edades | 18 Years – Sin máximo |
| Voluntarios sanos | No |
Elegibilidad tal como figura en el registro
Elegibilidad en frases sencillas
Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.
Diseño del estudio
| Tipo de estudio | De intervención |
|---|---|
| Fase | Fase 3 |
| Asignación | Aleatorizado |
| Modelo de intervención | PARALLEL |
| Propósito principal | TREATMENT |
| Enmascaramiento | QUADRUPLE (4) |
| Inscripción | 656 participantes buscados |
Patrocinador y colaboradores
- Pfizer Patrocinador
Grupos e intervenciones
- PlaceboPLACEBO_COMPARATOR
Participants will receive placebo as subcutaneous injection
- Arm 1: Berobenatide Once MonthlyEXPERIMENTAL
Participants will receive berobenatide by subcutaneous injection.
- Arm 2: Berobenatide Once MonthlyEXPERIMENTAL
Participants receive berobenatide by subcutaneous injection.
- Arm 3: Berobenatide Once MonthlyEXPERIMENTAL
Participants receive berobenatide by subcutaneous injection.
Intervenciones
- Fármaco Berobenatide
Subcutaneous Injection
- Otro Placebo
Subcutaneous Injection
Variables de resultado
Variable de resultado principal
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score
Plazo Baseline and Week 52
Variable de resultado secundaria
Percent change from baseline in Body Weight
Plazo Baseline and Week 52
Variable de resultado secundaria
Change From Baseline in High-Sensitivity C-Reactive Protein
Plazo Baseline and Week 52
Variable de resultado secundaria
Change from baseline in WOMAC Physical Function Subscale score
Plazo Baseline and Week 52
Variable de resultado secundaria
Percentage of participants with ≥50% reduction in the WOMAC pain subscale score
Plazo Baseline and Week 52
Variable de resultado secundaria
Percentage of participants with ≥30% reduction in the WOMAC pain subscale score
Plazo Baseline and Week 52
Variable de resultado secundaria
Proportion of participants with utilization of protocol specified pain medication during the washout period
Plazo Baseline and Week 52
Variable de resultado secundaria
Amount of protocol specified pain medication during the washout period
Plazo Baseline and Week 52
Variable de resultado secundaria
Change from baseline in WOMAC stiffness score
Plazo Baseline and Week 52
Variable de resultado secundaria
Change from baseline in WOMAC total score
Plazo Baseline and Week 52
Variable de resultado secundaria
Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score
Plazo Baseline and Week 52
Variable de resultado secundaria
Proportion of participants meeting OMERACT-OARSI
Plazo Baseline and Week 52
Variable de resultado secundaria
Change from baseline in Average Pain Intensity-Numerical Rating Score
Plazo Baseline and Week 52
Variable de resultado secundaria
Change from baseline in Worst Pain Intensity -Numerical Rating Score
Plazo Baseline and Week 52
Variable de resultado secundaria
Change from baseline in SF-36 domain scales and component summary scales
Plazo Baseline and Week 52
Variable de resultado secundaria
Change from baseline in Body Weight
Plazo Baseline and Week 52
Variable de resultado secundaria
Change from Baseline in Body Mass Index
Plazo Baseline and Week 52
Variable de resultado secundaria
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Plazo Baseline and Week 52
Variable de resultado secundaria
Number of Participants with Serious Adverse Events (SAE)
Plazo Baseline and Week 52
Variable de resultado secundaria
Number of Participants with AE leading to permanent discontinuation from study intervention or study
Plazo Baseline and Week 52
Variable de resultado secundaria
Number of Participants with Adverse Events of Special Interest (AESI)
Plazo Baseline and Week 52
Variable de resultado secundaria
Number of Participants with Clinical laboratory abnormalities
Plazo Baseline and Week 52
Variable de resultado secundaria
Change from baseline in timed walking distance at Week 52
Plazo Baseline and Week 52
Variable de resultado secundaria
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function
Plazo Baseline and Week 52
Variable de resultado secundaria
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain
Plazo Baseline and Week 52
Variable de resultado secundaria
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function
Plazo Baseline and Week 52
Variable de resultado secundaria
Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain
Plazo Baseline and Week 52
Variable de resultado secundaria
Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score
Plazo Baseline and Week 52
Variable de resultado secundaria
Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score
Plazo Baseline and Week 52
Variable de resultado secundaria
Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score
Plazo Baseline and Week 52
Variable de resultado secundaria
Change From Baseline in WPAI:GH Work productivity loss score
Plazo Baseline and Week 52
Variable de resultado secundaria
Change From Baseline in WPAI:GH Activity impairment score
Plazo Baseline and Week 52
Variable de resultado secundaria
Change From Baseline in Systolic Blood Pressure (SBP)
Plazo Baseline and Week 52
Variable de resultado secundaria
Change From Baseline in Diastolic Blood Pressure (DBP)
Plazo Baseline and Week 52
Variable de resultado secundaria
Change From Baseline in Total Cholesterol
Plazo Baseline and Week 52
Variable de resultado secundaria
Change From Baseline in High-density lipoprotein cholesterol (HDL-C)
Plazo Baseline and Week 52
Variable de resultado secundaria
Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)
Plazo Baseline and Week 52
Variable de resultado secundaria
Change from baseline in Non-HDL Cholesterol
Plazo Baseline and Week 52
Variable de resultado secundaria
Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol
Plazo Baseline and Week 52
Variable de resultado secundaria
Change from baseline in Triglycerides
Plazo Baseline and Week 52
Fechas
| Fecha de inicio | 26 de octubre de 2026 (real) |
|---|---|
| Finalización principal | 22 de agosto de 2028 (estimada) |
| Finalización | 10 de octubre de 2028 (estimada) |
| Primera publicación | 5 de noviembre de 2026 (real) |
| Última actualización | 5 de noviembre de 2026 |
| Resultados publicados | No indicado en el registro |
| Estado verificado por última vez | octubre de 2026 |
Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.
Ubicaciones
7 centros están en reclutamiento
Canada
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Bluewater Clinical Research Group Inc. | Sarnia | Ontario | Aún no recluta |
United States
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Albuquerque Clinical Trials, Inc. | Albuquerque | New Mexico | Aún no recluta |
| Charlottesville Medical Research Center, LLC | Charlottesville | Virginia | Aún no recluta |
| Northwestern University Feinberg School Of Medicine | Chicago | Illinois | Aún no recluta |
| Great Lakes Clinical Trials, LLC dba Flourish Research | Chicago | Illinois | Aún no recluta |
| Northwestern Medicine | Chicago | Illinois | Aún no recluta |
| Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG) | Chicago | Illinois | Aún no recluta |
| Northwestern Memorial Hospital, Investigational Drug Service | Chicago | Illinois | Aún no recluta |
| Clinical Research of West Florida, Inc. | Clearwater | Florida | Aún no recluta |
| Skylight Health Research | Colorado Springs | Colorado | Aún no recluta |
| Mercy Family Clinic | Dallas | Texas | Aún no recluta |
| Universal Axon Clinical Research LLC | Doral | Florida | En reclutamiento |
| Altoona Center For Clinical Research | Duncansville | Pennsylvania | En reclutamiento |
| Headlands Research California, LLC | Escondido | California | Aún no recluta |
| Profound Research LLC | Farmington Hills | Michigan | En reclutamiento |
| Cedar Health Research | Fort Worth | Texas | Aún no recluta |
| Novant Health Granite Quarry Internal Medicine (knee x-ray) | Granite Quarry | North Carolina | Aún no recluta |
| BRCR Global Louisiana | Gretna | Louisiana | Aún no recluta |
| JCCT-JUNO NW Houston | Houston | Texas | Aún no recluta |
| Westside Center for Clinical Research | Jacksonville | Florida | Aún no recluta |
| Activian Clinical Research | Kingwood | Texas | Aún no recluta |
| Renstar Medical Research | Lady Lake | Florida | Aún no recluta |
| Monroe Biomedical Research | Monroe | North Carolina | En reclutamiento |
| AMR Clinical | Norman | Oklahoma | Aún no recluta |
| Renstar Medical Research | Ocala | Florida | Aún no recluta |
| Prospective Research Innovations Inc. | Rancho Cucamonga | California | Aún no recluta |
| Accellacare - Salisbury | Salisbury | North Carolina | Aún no recluta |
| Consano Clinical Research, LLC | Shavano Park | Texas | Aún no recluta |
| Revive Research Institute, Inc. | Sterling Heights | Michigan | En reclutamiento |
| Clinical Research Atlanta | Stockbridge | Georgia | Aún no recluta |
| Clinical Research of West Florida, Inc. | Tampa | Florida | Aún no recluta |
| AMR Clinical | Tempe | Arizona | Aún no recluta |
| DM Clinical Research | Tomball | Texas | Aún no recluta |
| Solace Clinical Research | Tustin | California | Aún no recluta |
| Velocity Clinical Research, Waco | Waco | Texas | Aún no recluta |
| Elevate Clinical Research | Wichita | Kansas | Aún no recluta |
| Delaney Radiologist | Wilmington | North Carolina | En reclutamiento |
| Accellacare | Wilmington | North Carolina | En reclutamiento |
| North Georgia Internal Medicine | Woodstock | Georgia | Aún no recluta |
| North Georgia Clinical Research, LLC | Woodstock | Georgia | Aún no recluta |
Documentos del estudio
No hay documentos enlazados en este registro.
Cambios a lo largo del tiempo
No se han registrado cambios desde que incorporamos este registro por primera vez.
Se registra un cambio cada vez que el patrocinador actualiza el registro. El estado, las fechas, la inscripción y los centros aparecen aquí a medida que cambian.